Naari Pharma Private Limited, through its wholly owned subsidiary Naari Pte, has entered into a definitive asset purchase agreement to acquire 10 Abbreviated New Drug Applications (ANDAs) for the U.S. market from Intas Pharmaceuticals Ltd.
The portfolio acquired comprises eight U.S. FDA approved ANDAs and two products pending approval. It includes generic products in female hormones which will be manufactured at Naari’s dedicated female hormone facility in India and commercialized over the next 24 months.
Naari is a vertically integrated global women’s health pharmaceutical business focused on hormones and has development and manufacturing capabilities across intermediates, active pharmaceutical ingredients, and finished dosage forms (FDFs).
“This is great news for us and another milestone in our journey towards becoming a leading global player in the field of women’s health,” Prithi S Kochhar, Co-Founder and CEO of Naari, said. “This is an important step towards developing our U.S. portfolio. With these newly acquired ANDAs we now have market access of USD 900 million as per IQVIA data.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
The acquisition follows a planned period of significant growth and investment for Naari. In October 2019 Naari acquired three ANDAs from OC Pharm in the U.S. and in February 2020 the company announced that it had received an equity investment of USD 17.5 million from Ascent Capital, a leading India-focused growth capital provider.
With a presence in more than 50 countries and over 30 hormonal generics currently available or under development, Naari has one of the most comprehensive hormonal portfolios in the world.
Intas is a multinational pharmaceutical formulation development, manufacturing and marketing company with a presence in more than 85 countries worldwide. Estimated to be worth $4.25 billion, Intas is one of the most valued private pharmaceutical companies in India.